X

Trial Profile

A Phase I Study to Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment in Patients With Solid Tumor

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MG-D-1509 (Primary) ; MG-005; Sorafenib
Indications Liver cancer; Lung cancer; Renal cancer; Solid tumours
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Metagone Biotech

Most Recent Events

31 Aug 2020 Status changed from recruiting to completed.
15 Aug 2018 Status changed from not yet recruiting to recruiting.
20 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Jun 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com